Bayer, Inc. Xarelto product monograph. Toronto (ON); 2013.
3.
Pfizer Canada, Inc. Eliquis product monograph. Kirkland (ON); 2012.
4.
SchulmanSCrowtherMA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood2012;119:3016-23.
5.
LevyJHKeyNSAzranMS. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology2010;113:726-45.
6.
TrujilloTC. Emerging anticoagulants for venous thromboembolism prevention. Am J Health Syst Pharm2010;67(suppl 6):S17-25.
7.
Dabigatran etexilate. In: DRUGDEX System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available: http://www.micromedexsolutions.com (accessed Aug. 7, 2013).
8.
Rivaroxaban, In: DRUGDEX System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available: http://www.micromedexsolutions.com (accessed Aug. 7, 2013).
9.
DouketisJD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Design2010;16:3436-41.
HornJRHanstenPD. Drug interactions with digoxin: the role of P-glycoprotein. Pharmacy Times2004;Oct:45, 114.
13.
SpyropoulosACDouketisJD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood2012;120:2954-62.
14.
BarrettYCWangZFrostCShenkerA. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost2010;104:1263-71.
15.
SamamaMMGuinetC. Laboratory assessment of new anticoagulants. Clin Chem Lab Med2011;49:761-72.
16.
MiyaresMADavisK. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm2012;69:1473-84.
17.
BauerKA. Reversal of antithrombotic agents. Am J Hematol2012;87:S119-26.
18.
KaatzSKouidesPAGarciaDA. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol2012;87:S141-5.
19.
van RynJSiegerPKink-EibandM. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro. In: 51st ASH Annual Meeting and Exposition, New Orleans (LA): American Society of Hematology; 2009. Available: http://ash.confex.com/ash/2009/webprogram/Paper21383.html (accessed Aug. 7, 2013).
20.
StangierJRathgenKStahleHMazurD. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet2010;49:259-68.
